Isotiorga

Isotretinoin, the active ingredient in Isotiorga, is a retinoid presented as an oral formulation for oral use. It is indicated for the treatment of severe recalcitrant nodular acne in patients who have not responded to conventional therapies. It works by reducing sebaceous gland size and sebum production while exerting anti‑inflammatory effects, leading to marked improvement in lesion count.

GNH USA supplies Isotiorga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across multiple markets.

Isotiorga (isotretinoin) belongs to the retinoid class and is used to treat severe forms of acne.

Severe nodular acne: reduces inflammatory lesions, prevents new nodule formation and improves skin appearance. Severe cystic acne: decreases cyst size and number, leading to reduced scarring risk. Acne conglobata: helps control extensive, treatment‑resistant disease by shrinking lesions and limiting spread.

Isotiorga may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry skin: excessive epidermal dryness and scaling. - Cheilitis: cracked, painful lips. - Xerosis of mucous membranes: dryness of eyes and nasal passages. - Elevated triglycerides: increase in serum lipid levels. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Teratogenicity: severe birth defects if exposure occurs during pregnancy. - Depression or suicidal ideation: mood changes requiring immediate evaluation. - Inflammatory bowel disease: onset or worsening of ulcerative colitis or Crohn’s disease. - Liver toxicity: elevated transaminases indicating hepatic injury.

Before initiating Isotiorga, several safety considerations should be reviewed. - Pregnancy contraindication: avoid use in pregnant women; teratogenic risk is category X. - Contraception requirement: women of childbearing potential must use two reliable forms of birth control. - Lipid monitoring: baseline and periodic serum triglyceride measurements are advised. - Liver function monitoring: check hepatic enzymes before treatment and during therapy. - Vitamin A intake: avoid concurrent high‑dose vitamin A supplements to prevent toxicity. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Isotiorga can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Tetracycline antibiotics: increased risk of intracranial hypertension. - Vitamin A supplements: additive risk of hypervitaminosis A. - St. John’s wort: may reduce isotretinoin plasma concentrations.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive effectiveness. - Anticoagulants (e.g., warfarin): isotretinoin may enhance anticoagulant effect, requiring INR monitoring. - Retinoid topical agents: combined use can intensify skin irritation. - Lipid‑lowering agents (e.g., fibrates): may increase risk of hypertriglyceridemia.